Business Wire

Suzano Reports a Strong Second Quarter Performance With Record Cash Generation

Share

Suzano, one of the world’s largest integrated pulp and paper producers, announces its second quarter results for 2022.

  • Adjusted EBITDA of R$6.3 billion, up 6% on 2Q21 (R$5.9 billion)
  • Operating cash generation of R$5.1 billion, up 2% on 2Q21 (R$4.9 billion)
  • Net revenue of R$11.5 billion, up 17% on 2Q21 (R$9.8 billion)
  • Substantial sales volume increase:
    • 5% increase in pulp sales volumes to 2.66 million tons (2Q21: 2.54 million tons)
    • 10% increase paper sales volumes to 324,000 tons (2Q21: 296,000 tons)
  • Net debt to EBITDA leverage ratio of 2.3x (1Q22: 2.4x)
  • Increased 2022 CAPEX guidance of R$16.1 billion from previously announced R$13.6 billion

Strong second quarter performance across these financial verticals was driven by both higher sales prices, given more favourable market conditions for pulp and paper markets; and higher sales volumes, given fewer scheduled maintenance shutdowns. Cost management discipline also improved adjusted EBITDA and cash generation.

“These excellent second quarter results are not only testament to higher pulp prices and positive market demand, but as well as the continued efforts of our various teams to ensure Suzano boosts operational efficiency. With this firm financial and operational footing, Suzano is intent on expanding our capacity to create, and share, value with our stakeholders,” said Walter Schalka, CEO of Suzano.

The Cerrado Project, a new pulp plant which is being built in Mato Grosso do Sul state, is progressing precisely as scheduled, closing the second quarter of 2022 with a physical progress "inside-the-fence" of 21%. This one plant alone will create up to 10,000 direct jobs during construction and 3,000 new employment opportunities once operational.

The second quarter also saw the acquisition of land properties, the launch of Suzano Ventures, and new plans to build a consumer goods plant in Espírito Santo. Additionally, in recent months Suzano has announced a higher dividend payment in 2022 and a share buyback program, with a new buyback program announced today.

On a social front, Suzano intends to double the number of beneficiaries attended by its social programs to 50,000 people in 2022. Meanwhile, on an environmental front, the numerous projects under development include one of the largest landscape restoration programs in Brazil, covering 35,000 hectares of areas under restoration, and the goal of connecting 500,000 hectares of forest fragments by 2030.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Hawthorn Advisors
Jamie Plotnek
suzano@hawthornadvisors.com

About Business Wire

Business Wire
Business Wire



Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Kapruvia ® approved in Switzerland with additional regulatory decisions expected in H2 202219.8.2022 07:00:00 CEST | Press release

Vifor Fresenius Medical Care Renal Pharma (VFMCRP) and Cara Therapeutics, Inc. (Nasdaq: CARA) today announced that they have received approval for Kapruvia® from the Swiss Agency for Therapeutic Products (Swissmedic). Kapruvia® will be the first therapy available for the treatment of moderate-to-severe pruritus associated with chronic kidney disease in adult hemodialysis patients. Swissmedic approval for Kapruvia® follows approvals by the U.S. Food and Drug Administration, by the European Medicines Agency, by the UK Medicines and Healthcare products Regulatory Agency, as well as by Health Canada. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220818005552/en/ “The approval of Kapruvia® in Switzerland is the next step on our journey to bring this breakthrough treatment to hemodialysis patients living with CKD-associated pruritus around the world,” said Dr. Klaus Henning Jensen, Chief Medical Officer of CSL Vifor. “There is a

European Commission Approves Celltrion Healthcare’s Vegzelma™ (CT-P16, biosimilar bevacizumab) for the Treatment of Multiple Types of Cancer19.8.2022 04:47:00 CEST | Press release

Celltrion Healthcare announced today that the European Commission (EC) has approved Vegzelma™ (CT-P16), a biosimilar bevacizumab referencing EU-approved Avastin®, for the treatment of metastatic breast cancer, non-small cell lung cancer, advanced and/or metastatic renal cell cancer, metastatic carcinoma of the colon or rectum, ovarian cancer and cervical cancer. “The European Commission’s approval of Vegzelma™ will increase access to treatment for patients living with certain types of cancer at an affordable price,” said Kevin Byoung Seo Choi, Senior Vice President and Head of Marketing Division at Celltrion Healthcare. “With proven similarities in efficacy and safety compared to the reference product Avastin®, Vegzelma™ will be available to treat some of the most commonly diagnosed cancers, which collectively affect hundreds of thousands of European patients each year.” The EC approval of Vegzelma™ follows the recommendation for marketing authorisation issued by the Committee for Medi

Dermaliq Therapeutics announces first patient dosed in Phase 1b/2 trial evaluating DLQ02 for treatment of plaque psoriasis18.8.2022 18:27:00 CEST | Press release

Dermaliq Therapeutics, Inc. (Dermaliq), a private, clinical stage pharmaceutical company with a focus on dermatology, today announced first patient dosed in a Phase 1b/2a trial with DLQ02, a topical calcineurin inhibitor. The trial is designed to evaluate the safety, systemic absorption, pharmacodynamics, and clinical efficacy of DLQ02 in patients with plaque psoriasis. “DLQ02 evaluates for the first time hyliQTM, a novel platform technology in dermatology to create best in-class topical therapies with superior bioavailability,” said Betsy Hughes-Formella, PhD, Chief Scientific Officer at Dermaliq. “Calcineurin inhibitors for the treatment of psoriasis are a standard of care when given orally, albeit being associated with significant risk for systemic side effects. DLQ02 is designed to overcome the challenges of topical delivery of this drug class with reduced risk profiles. We are convinced DLQ02 has the potential to transform topical psoriasis therapy for millions of patients.” The r

Aero Secures $65M in Series B Financing to Accelerate the Future of Premium Air Travel18.8.2022 18:00:00 CEST | Press release

Aero Technologies, Inc. the next-generation premium air travel company, which serves routes in both the US and Europe, today announced a $65M capital raise, $50M in Series B funding and $15M in convertible notes, for a total post-money valuation of $300M. The funding round was co-led by AlbaCore Capital Group, one of Europe’s leading alternative investment firms, and returning investors Expa and Keyframe Capital, with new investment from Capital One Ventures. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220818005095/en/ (Photo: Business Wire) Inspired by the golden age of aviation and designed for modern life, Aero is redefining semi-private air travel. Aero serves premium leisure travelers through private terminals, enriching the experience with personalized Concierge services - from booking to touchdown. With its fleet of sleek, black planes, Aero offers elevated, effortless guest experiences to curated destinations with

Veristat is Recognized on the 2022 Inc. 5000 List of America’s Fastest-Growing Private Companies18.8.2022 15:49:00 CEST | Press release

Veristat, global experts in clinical development, registration and post-marketing solutions proudly announces its recognition once again by Inc. Magazine as one of the 5000 fastest-growing private companies in the United States. Since its first appearance on the list in 2015, Veristat has significantly expanded in size, geographic reach and service offering to swiftly guide novel therapies through their clinical development process to regulatory approval and commercialization. Veristat’s team of scientific experts works collaboratively with clients in the biotech and pharmaceutical industries to overcome the many challenges associated with bringing to market products that address current medical shortcomings and maintain their good standing. “Being recognized as one of America’s Fastest-Growing Private Companies is a testament to Veristat’s ability to deliver innovative solutions, bold thinking and versatile engagement models to our clients,” stated Patrick Flanagan, Chief Executive Of

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom